Vanguard Group Inc Macrogenics Inc Transaction History

Vanguard Group Inc

$4.96 Trillion
Q1 2024

A detailed history of Vanguard Group Inc transactions in Macrogenics Inc stock. As of the latest transaction made, Vanguard Group Inc holds 3,677,678 shares of MGNX stock, worth $15.6 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

3,677,678

Previous 4,309,394 14.66%

Holding current value

$15.6 Million

Previous $41.5 Million 30.58%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$9.77 - $21.47 $6.17 Million - $13.6 Million	-631,716 Reduced 14.66%	3,677,678 $54.1 Million
Q4 2023 Feb 14, 2024	SELL	$4.48 - $10.11 $472,774 - $1.07 Million	-105,530 Reduced 2.39%	4,309,394 $41.5 Million
Q3 2023 Nov 14, 2023	BUY	$4.48 - $6.19 $163,054 - $225,291	36,396 Added 0.83%	4,414,924 $20.6 Million
Q2 2023 Aug 14, 2023	SELL	$4.62 - $7.54 $415,204 - $677,627	-89,871 Reduced 2.01%	4,378,528 $23.4 Million
Q1 2023 May 15, 2023	BUY	$4.82 - $7.24 $115,848 - $174,013	24,035 Added 0.54%	4,468,399 $32 Million

Q4 2022 Feb 10, 2023	BUY	$5.62 - $6.98 $1.47 Million - $1.83 Million	262,123 Added 6.27%	4,444,364 $29.8 Million
Q3 2022 Nov 14, 2022	BUY	$3.01 - $5.22 $756,349 - $1.31 Million	251,279 Added 6.39%	4,182,241 $14.5 Million
Q2 2022 Aug 12, 2022	SELL	$2.25 - $9.99 $227,873 - $1.01 Million	-101,277 Reduced 2.51%	3,930,962 $11.6 Million
Q1 2022 May 13, 2022	BUY	$8.12 - $16.9 $698,815 - $1.45 Million	86,061 Added 2.18%	4,032,239 $35.5 Million
Q4 2021 Feb 14, 2022	BUY	$15.91 - $21.88 $796,104 - $1.09 Million	50,038 Added 1.28%	3,946,178 $63.3 Million
Q3 2021 Nov 12, 2021	SELL	$19.74 - $28.7 $886,799 - $1.29 Million	-44,924 Reduced 1.14%	3,896,140 $81.6 Million
Q2 2021 Aug 13, 2021	BUY	$20.49 - $35.63 $80.8 Million - $140 Million	3,941,064 New	3,941,064 $106 Million

Others Institutions Holding MGNX

# of Institutions

170

Shares Held

62.4M

Call Options Held

819K

Put Options Held

79.4K

View Full List

About MACROGENICS INC

Ticker MGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,458,800
Market Cap $261M
Description
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients ...

More about MGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Macrogenics Inc Transaction History